Jonathan Chang
Stock Analyst
(0.40)
# 4,648
Out of 4,648 analysts
91
Total ratings
29.17%
Success rate
-18.93%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jonathan Chang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VINC Vincerx Pharma | Maintains: Outperform | $4 → $2 | $0.36 | +458.66% | 6 | Oct 8, 2024 | |
| IMCR Immunocore Holdings | Initiates: Outperform | $74 | $31.17 | +137.41% | 1 | Apr 29, 2024 | |
| NBTX Nanobiotix | Initiates: Outperform | $11 | $4.21 | +161.28% | 1 | Dec 8, 2023 | |
| NVCR NovoCure | Initiates: Outperform | $51 | $16.59 | +207.41% | 1 | Aug 4, 2023 | |
| KPTI Karyopharm Therapeutics | Maintains: Market Perform | $6 → $5 | $0.93 | +435.91% | 12 | Jan 10, 2023 | |
| REPL Replimune Group | Maintains: Outperform | $30 → $34 | $12.02 | +182.86% | 9 | Dec 7, 2022 | |
| GMAB Genmab | Maintains: Market Perform | $31 → $33 | $22.78 | +44.86% | 9 | Nov 10, 2022 | |
| BCYC Bicycle Therapeutics | Maintains: Outperform | $48 → $50 | $23.46 | +113.13% | 4 | Aug 22, 2022 | |
| RVMD Revolution Medicines | Maintains: Outperform | $31 → $30 | $55.87 | -46.30% | 4 | Aug 10, 2022 | |
| MGNX MacroGenics | Maintains: Outperform | $15 → $12 | $3.70 | +224.32% | 8 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $14 | $1.84 | +660.87% | 5 | Aug 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $25 → $26 | $9.35 | +178.07% | 5 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $101 → $95 | $30.89 | +207.54% | 8 | May 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $2 → $3 | $0.83 | +262.54% | 8 | May 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $41 → $28 | $17.81 | +57.22% | 3 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 → $53 | $21.52 | +146.28% | 7 | Aug 5, 2021 |
Vincerx Pharma
Oct 8, 2024
Maintains: Outperform
Price Target: $4 → $2
Current: $0.36
Upside: +458.66%
Immunocore Holdings
Apr 29, 2024
Initiates: Outperform
Price Target: $74
Current: $31.17
Upside: +137.41%
Nanobiotix
Dec 8, 2023
Initiates: Outperform
Price Target: $11
Current: $4.21
Upside: +161.28%
NovoCure
Aug 4, 2023
Initiates: Outperform
Price Target: $51
Current: $16.59
Upside: +207.41%
Karyopharm Therapeutics
Jan 10, 2023
Maintains: Market Perform
Price Target: $6 → $5
Current: $0.93
Upside: +435.91%
Replimune Group
Dec 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $12.02
Upside: +182.86%
Genmab
Nov 10, 2022
Maintains: Market Perform
Price Target: $31 → $33
Current: $22.78
Upside: +44.86%
Bicycle Therapeutics
Aug 22, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $23.46
Upside: +113.13%
Revolution Medicines
Aug 10, 2022
Maintains: Outperform
Price Target: $31 → $30
Current: $55.87
Upside: -46.30%
MacroGenics
Aug 9, 2022
Maintains: Outperform
Price Target: $15 → $12
Current: $3.70
Upside: +224.32%
Aug 9, 2022
Maintains: Outperform
Price Target: $13 → $14
Current: $1.84
Upside: +660.87%
Jun 3, 2022
Maintains: Outperform
Price Target: $25 → $26
Current: $9.35
Upside: +178.07%
May 11, 2022
Maintains: Outperform
Price Target: $101 → $95
Current: $30.89
Upside: +207.54%
May 9, 2022
Maintains: Market Perform
Price Target: $2 → $3
Current: $0.83
Upside: +262.54%
Feb 25, 2022
Maintains: Outperform
Price Target: $41 → $28
Current: $17.81
Upside: +57.22%
Aug 5, 2021
Maintains: Outperform
Price Target: $57 → $53
Current: $21.52
Upside: +146.28%